More on CSLLY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $35.35 |
|
|||
| Open | $34.77 | ||||
| 52 Wk High | $45.60 | ||||
| 52 Wk Low | $33.39 | ||||
| Day High | $35.21 | ||||
| Day Low | $34.60 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 40,669 | ||||
- CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD225 at UBS
- CSL names Deborah Waterhouse as CEO, effective February 2027
- CSL appoints Deborah Waterhouse as CEO & Managing Director
- CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
- CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign
- CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD182.50 at Goldman Sachs
- Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
- CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD160 at Citi
- CSL Ltd. (CSL:AU) (CSLLY) PT Raised to AUD181 at UBS
- CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
Entities mentioned with CSLLY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- AdCom | View Related Stories »
- Vanguard | View Related Stories »
- JPMorgan | View Related Stories »
- S1 | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
